Mutations in genes encoding innate immune molecules identified in bladder cancer samples as potential biomarkers for immunotherapy with BCG and agonists

Bacillus Calmette–Guérin (BCG) immunotherapy for the treatment of bladder cancer (BC) depends on recognition bacteria by extracellular toll-like receptors (TLRs) or detection mycobacterial DNA endosomal TLRs cGAS-STING pathway. Agonists related to these innate immune pathways have been developed as adjuvants potentiate effects immunotherapy. As are important action BCG and other agonists proposed BC therapy, we decided investigate presence mutations in main pathways. The Cancer Genome Atlas (TCGA) database was screened identify BC-related (apart from oncogenes), targeting, particular, TLRs, adaptor molecule MyD88, (cyclic GMP-AMP synthase-stimulator interferon genes) Among 1,724 entries, 103 were identified 80 affected cases cohort. TLR9 TLR10 ranked among most frequent mutated genes observed our search (13 each). Through all analyzed data, MYD88 gene recovered only 1 mutation input database. Mutations STING cGAS found one four cases, respectively. We also evaluated clinical including pathologic stage BC, expression entries. This article attempts highlight relevance coding molecules samples potential biomarkers predict individual disease outcome, specifically help find appropriate each person future.